The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia
File version
Author(s)
de Guingand, Deborah
Reddy, Maya
Rowson, Saskia
Rolnik, Daniel L
Davey, Mary-Ann
Mol, Ben W
Wallace, Euan M
Da Silva Costa, Fabricio
Palmer, Kirsten R
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Research indicates that soluble fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PLGF) have diagnostic and prognostic significance for women with preeclampsia. However, sparse research has studied these biomarkers in women with preexisting comorbidities such as chronic hypertension, diabetes mellitus, systemic lupus erythematosus and chronic kidney disease. We undertook a prospective longitudinal cohort study to compare the sFLT-1: PlGF ratio between women with and without comorbidities who did and did not go on to develop preeclampsia. We found that women with comorbidities may develop preeclampsia with a milder elevation in sFLT-1: PlGF than do women without comorbidities. This has clinical and research implications.
Journal Title
Pregnancy Hypertension
Conference Title
Book Title
Edition
Volume
29
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Obstetrics and gynaecology
Cardiovascular medicine and haematology
Clinical sciences
Science & Technology
Life Sciences & Biomedicine
Obstetrics & Gynecology
Peripheral Vascular Disease
Cardiovascular System & Cardiology
Persistent link to this record
Citation
Tanner, MS; de Guingand, D; Reddy, M; Rowson, S; Rolnik, DL; Davey, M-A; Mol, BW; Wallace, EM; Da Silva Costa, F; Palmer, KR, The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia, Pregnancy Hypertension, 2022, 29, pp. 98-100